




Advancing Transfusion and Cellular Therapies Worldwide

# AABB Survey: CCP usage re-evaluation March 2021


## Highlights

- ❑ Survey conducted from Mar. 15-17, 2021.
- ❑ 232 hospitals responded.
- ❑ Interest and openness to using CCP as a COVID treatment continues to be high. More hospitals (45%) have decided to continue transfusing CCP compared to the last survey (38%).
- ❑ Several respondents indicated that the orders to use CCP will depend on the infectious disease department or other clinicians.
- ❑ 21% are in the process of evaluating whether to continue CCP use or not.
- ❑ 9% (n=22) of the hospitals are planning to discontinue CCP or have already done so. Among these hospitals, lack of stronger efficacy data (64%) followed by plan to shift towards other treatments (41%) were the two most common factors for discontinuation.
- ❑ 79% of the hospitals have discussed the availability of high titer CCP with their blood supplier, higher compared to the last survey (73%).
- ❑ 49% of the hospitals are willing to continue transfusing CCP if the reimbursement structure changes to a more traditional model, lower compared to the last survey (55%).
- ❑ 34% of the hospitals believe both the availability of high titer units and cost will have the biggest impact on their CCP use in the future, higher compared to the last survey (30%).
- ❑ The majority of hospitals reported the use of CCP was entirely at the discretion of the ordering physician.

## Anticipated CCP usage




## Reasons to discontinue use of CCP\*



\* Response ratio presented based on a multi-select question. 22 hospitals responded as planning to discontinue CCP use or have already done so in the March 2021 Survey.

## Discussed the availability of high titer CCP with blood supplier







Advancing Transfusion and Cellular Therapies Worldwide

# AABB Survey: CCP usage re-evaluation March 2021

## Biggest impact on CCP use in the future



## Continue to transfuse CCP if the reimbursement structure changes



## Patient selection and CCP use

